When theT-cell-seeded alginate implant was placed at the tumor site, remarkableefficacy and T cell expansion was observed in treating tumor resectionand inoperable tumor mouse models.23 Ina follow-up, STING agonists were delivered in the alginate implantsalong with adoptive T cells.464 This codeliverymethod enabled eradication of tumor cells that did not express theT-cell-targeted antigen, eliciting global tumor immunity and treatmentof heterogeneous tumors. This evidence concerns the gene STING1 and neoplasm.